Combinatorial fedratinib and venetoclax treatment is effective on human B cell acute lymphoblastic leukemia with high Flt3 expression.
Sean P RinellaHaley C BellDavid P TuricekLei ShiNguyet-Minh HoangLixin RuiNicholas J HessChristian M CapitiniPublished in: bioRxiv : the preprint server for biology (2023)
B-ALL in vitro. Gene set enrichment analysis of RNA from B-ALL treated with fedratinib and venetoclax identified dysregulation of pathways associated with apoptosis, DNA repair and proliferation.Combination fedratinib and venetoclax reduces the number of peripheral blood B-ALL blasts in vivo, improving overall survival while also increasing CD19 expression.
Keyphrases
- dna repair
- acute lymphoblastic leukemia
- poor prognosis
- peripheral blood
- chronic lymphocytic leukemia
- dna damage
- endothelial cells
- acute myeloid leukemia
- oxidative stress
- endoplasmic reticulum stress
- copy number
- genome wide
- combination therapy
- pluripotent stem cells
- transcription factor
- induced pluripotent stem cells